Ontogenetic changes in serum S100B in Down syndrome patients.
It has been shown that Down syndrome (DS) patients have elevated S100B levels in brain tissue. Measurements of S100B were performed in serum samples from 48 DS patients and 42 ostensibly healthy age-matched controls. We observed higher levels of S100B in the DS group than in the control group. Moreover, serum S100B in DS patients was not age-dependent as it is in normal individuals. The higher levels of S100B in DS patients may reflect a general and persistent increase in the extracellular space and may be associated with neurodegenerative lesions observed in DS patients.